Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Millennium Management LLC raised its stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) by 151.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 84,829 shares of the company’s stock after buying an additional 51,139 shares during the period. Millennium Management LLC owned about 0.20% of DiaMedica Therapeutics worth $461,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in DiaMedica Therapeutics by 14.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company’s stock valued at $105,000 after buying an additional 2,380 shares during the last quarter. LPL Financial LLC increased its stake in shares of DiaMedica Therapeutics by 8.2% in the 4th quarter. LPL Financial LLC now owns 152,000 shares of the company’s stock worth $825,000 after purchasing an additional 11,500 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $79,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $81,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $83,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Trading Down 1.4%

Shares of NASDAQ:DMAC opened at $4.08 on Tuesday. DiaMedica Therapeutics Inc. has a 12 month low of $2.14 and a 12 month high of $6.82. The company has a 50-day moving average price of $3.92 and a 200 day moving average price of $4.99. The company has a market cap of $174.96 million, a price-to-earnings ratio of -7.29 and a beta of 1.23.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). During the same quarter in the prior year, the company posted ($0.14) earnings per share. As a group, equities analysts forecast that DiaMedica Therapeutics Inc. will post -0.59 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of DiaMedica Therapeutics in a report on Thursday, May 29th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.